Pfizer Upbeat After Bagging Besponsa Approval in US
It is the first CD22-directed antibody-drug conjugate indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, though sales potential is modest.
It is the first CD22-directed antibody-drug conjugate indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, though sales potential is modest.